New recommendations aim to eliminate racial bias in myeloma trials
Flu vaccination: Lansley reforms caused London to fall behind in uptake, report finds
18 February 2021US policy requires immediate release of records to patients
18 February 2021New recommendations aim to eliminate racial bias in myeloma trials
Researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) are releasing recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.
